Linked Life Data

12831329

Source:http://linkedlifedata.com/resource/pubmed/id/12831329

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2003-6-30
pubmed:abstractText
The people of Anadys are committed to advancing patient care by discovering, developing, and commercializing novel and powerful anti-infective medicines. Anadys is focused on the discovery and development of small molecule therapeutics for the treatment of infectious disease, including hepatitis C and bacterial infections. The company's lead program for the treatment of hepatitis C is currently in Phase IB testing. Anadys also has a broad portfolio of antiviral and antibacterial programs directed at novel targets, intervention points and mechanisms of action. With an integrated suite of technologies and capabilities, including Riboproteomics, ATLAS and structure-based drug design through a world-class medicinal chemistry team, Anadys is capable of quickly optimizing lead compounds for use in preclinical and clinical testing. The company's goal is to build a strong and continual pipeline of novel and powerful drug candidates directed to advance patient care.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1462-2416
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
511-8
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Anadys Pharmaceuticals, Inc.
pubmed:affiliation
Senior Manager, Corporate Development & Strategy, Anadys Pharmaceuticals, Inc., 9050 Camino Santa Fe, San Diego, CA 92121, USA. basbaum@anadyspharma.com
pubmed:publicationType
Journal Article